Functionalizing avß3- or a5ß1-selective integrin antagonists for surface coating: A new tool to discriminate integrin subtypes in vitro by Rechenmacher, Florian et al.
Supporting Information
 Wiley-VCH 2013
69451 Weinheim, Germany
Functionalizing avb3- or a5b1-Selective Integrin Antagonists for
Surface Coating: A Method to Discriminate Integrin Subtypes
In Vitro**
Florian Rechenmacher, Stefanie Neubauer, Julien Polleux, Carlos Mas-Moruno,
Mariarosaria De Simone, Elisabetta Ada Cavalcanti-Adam, Joachim P. Spatz, Reinhard Fssler,
and Horst Kessler*
anie_201206370_sm_miscellaneous_information.pdf
 S2 
Table of Contents 
 
Methods 
Supplementary Figures 
General Procedures and Synthesis 
References 
 S3 
Methods 
Nanopatterned gold surfaces  
In a typical synthesis, 7 mg/mL of polystyrene(154)-block-poly(2-
vinylpyridine)(33) (PS154-b-P2VP33, Polymer Source) was dissolved at room 
temperature in p-xylene (Sigma-Aldrich, St. Louis, USA) and stirred for 2 days. 
The quantity of inorganic precursor was calculated relative to the number of 
P2VP units (NP2VP) and defined as the loading parameter (L). L was kept 
constant in all experiments, equal to 0.5 (i.e., 1 molecule of HAuCl4 per 2 P2VP 
units). Hydrogen tetrachloroaurate (III) trihydrate (HAuCl4∙3H2O; Sigma-Aldrich) 
was added to the block copolymer solution and stirred for 2 days in a sealed 
glass vessel.  
Glass coverslips (Carl Roth, Karlsruhe, Germany) were cleaned in a piranha 
solution for at least 5 h and extensively rinsed with MilliQ water and dried under a 
stream of nitrogen. Micellar monolayers were prepared by dip-coating a glass 
coverslip into the previously prepared solutions with a constant velocity equal to 
24 mm/min. Finally, to remove the organic template and form inorganic 
nanoparticles, the dip-coated glass slides were exposed to oxygen plasma (150 
W, 0.15 mbar, 45 min, PVA TEPLA 100 Plasma System). 
To prevent nonspecific protein adsorption or cell binding, the substrate area 
surrounding or in between the gold nanoparticles was covalently modified with 
polyethylene glycol (PEG; molecular weight 2000).[1] The gold nanoparticles were 
then functionalized with peptidomimetics by incubating the PEG-functionalized 
substrates in 100 μl of a 100 μM ethanolic solution. The substrates were then 
thoroughly rinsed with ethanol and water, incubated overnight in water, and 
finally dried with nitrogen. 
 
Cell experiments  
Mouse fibroblast cell lines expressing either αvβ3 or α5β1 were generated from 
fibroblasts derived from the kidney of αvflox/flox, β1flox/flox, β2-/- , β7-/- mice 
(manuscript in preparation). Cells were immortalized by retroviral transduction of 
the SV40 large T and cloned. Subsequently the cells were retrovirally transduced 
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with mouse αv or β1 integrin expression constructs. Endogenous β1 and αv 
integrin loci were deleted by adenoviral cre-recombinase transduction. Selective 
expression of αvβ3 or α5β1 was verified by flow cytometry and immunoblotting. 
Single integrin-expressing fibroblasts were cultivated by using DMEM 
supplemented with 10% FBS (both from Gibco, Invitrogen, Darmstadt, Germany), 
1% penicillin / streptomycin (PAA, Cölbe, Germany) in a culture incubator at 
37 °C in an atmosphere containing 5 % CO2. After reaching 80% confluence, 
cells were first rinsed with sterile PBS and then released with a 1% trypsin-EDTA 
solution (Gibco, Invitrogen, Darmstadt, Germany) for about 3-5 minutes. 
Trypsinisation was stopped by adding 10% FBS supplemented DMEM to the 
released cells, which were centrifuged at 900 rpm for 3 minutes. The resulting 
cell pellet was resuspended in pre-warmed growth medium and the cells were 
seeded again in cell culture dishes. 
To test the selectivity of compounds 3 and 4, both cells lines were serum-starved 
overnight, trypsinised, resuspended in DMEM containing 0.5 % FBS and seeded 
(approximately 2·103 cells) on functionalized gold nanoarrays. Live cell imaging 
was performed at 37°C and 5% CO2 on a Zeiss Axiovert 200M microscope with a 
10×1.6 objective; the microscope was equipped with a motorized stage 
(Märzhäuser, Wetzlar, Germany), an environment chamber (EMBL Precision 
Engineering, Heidelberg, Germany) and a cooled CCD camera (Roper Scientific, 
Princeton, NJ). Time-lapse movies (30 frame per second) were made by 
capturing images every 5 minutes for 6 hours. Spreading area was manually 
quantified with ImageJ (version 1.43u)[2] on a population of 30 cells. Error bars 
correspond to the standard deviation. 
 
Competitive solid-phase integrin binding assay 
The in vitro inhibition of integrin – extracellular matrix protein binding was 
measured using a solid-phase binding assay with soluble integrins and coated 
extracellular matrix ligands. Human integrin v3 was purchased from Millipore, 
51 from R&D Systems and IIb3 from Enzyme Research Laboratories. 
Vitronectin was purchased from Millipore, fibronectin from Sigma and fibrinogen 
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from Calbiochem. The integrin antibodies were purchased from Pharmingen, BD 
Bioscience Europe (mouse anti-human CD49e, mouse anti-human CD51/CD61 
and mouse anti-human CD41b) and Sigma (anti-mouse IgG-peroxidase). The 
detection of HRP was performed using HRP substrate solution 3.3.5.5’-
tetramethylethylenediamine (TMB, Seramun, Germany) and 3 M H2SO4 for 
stopping the reaction. The absorbance (450 nm) was recorded with a POLARstar 
Galaxy plate reader (BMG Labtechnologies). Every concentration was analyzed 
in duplicates and the resulting inhibition curves were analyzed using OriginPro 
7.5G software, the turning point describes the IC50 value. Each plate contained 
Cilengitide[3] or Tirofiban[4] as internal control. Blocking and binding steps were 
always performed with TS buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
CaCl2, 1 mM MgCl2, and 1 mM MnCl2) containing 1% BSA (TSB-buffer). 
Washings after each incubation step were done with PBST buffer (10 mM 
Na2HPO4 pH 7.5, 150 mM NaCl, and 0.01% Tween 20). 
Fibronectin-51 assay. Flat-bottom 96-well ELISA plates were coated 
overnight at 4 °C with 100 µL/well of 0.50 μg/mL of fibronectin in 15 mM of 
Na2CO3, 35 mM NaHCO3, pH 9.6 (carbonate buffer). Plates were subsequently 
blocked for 1 h at room temperature. Next, 1.0 µg/mL of soluble integrin 51 
and a serial dilution of integrin inhibitors and the control Cilengitide were 
incubated in the coated wells for 1 h at room temperature. After washing three 
times, the plate was treated with 100 μL/well of primary antibody (CD49e) at 1.0 
μg/mL (1:500 dilution) and secondary antibody (anti-mouse IgG-peroxidase) at 
2.0 μg/mL (1:385 dilution) for 1 h each at room temperature. After this treatment 
the plate was washed three times and the binding visualized with TMB as 
previously described.  
Vitronectin-v3 assay. For the αvβ3 assay, plates were coated with vitronectin 
(1.0 μg/mL) in carbonate buffer and blocked as described for α5β1. Soluble αvβ3 
(1.0 μg/mL) was incubated with a serial dilution of integrin inhibitors and the 
control Cilengitide for 1 h at room temperature. After washing three times, 
primary (CD51/CD61, 2.0 µg/mL, 1:250 dilution) and secondary antibody (anti-
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mouse-HRP conjugate, 1.0 µg/mL, 1:770 dilution) were applied for 1 h each at 
room temperature and the binding visualized as explained for 51.  
Fibrinogen-IIb3 assay. Flat-bottom 96-well ELISA plates were coated 
overnight at 4 °C with 100 µL/well of 10.0 μg/mL of fibrinogen in carbonate buffer. 
After blocking the plates, 2.5 µg/mL of soluble integrin IIb3 and a serial dilution 
of integrin inhibitors and the control molecule Tirofiban were incubated in the 
coated wells for 1 h at room temperature. The plate was then washed three times 
and subsequently treated with 100 μL/well of primary antibody (CD41b) at 2.0 
μg/mL (1:250 dilution) and secondary antibody (anti-mouse IgG-peroxidase) at 
1.0 μg/mL (1:770 dilution) for 1 h each at room temperature. The binding was 
visualized as explained above. 
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Supplementary Figures 
 
 
Figure S1: Diagram displaying the percentage of spread and round cells 
expressing α5β1 or αvβ3 integrin on gold nanoarrays functionalized with α5β1- or 
αvβ3-ligands in culture for 1h and 6h. A population of about 100 cells has been 
considered. 
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Figure S2: Diagram displaying the spreading area of α5β1- and αvβ3-expressing 
cells at two different time points on gold nanoarrays functionalized with α5β1- 
and αvβ3-selective compounds. The number of analyzed cells for each 
population is n = 30. 
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General Procedures and Synthesis  
Solvents and Reagents. Solvents were purchased from Aldrich, Fluka, Merck 
and Prolabo. Reactions sensible to oxygen or water were performed in flame-
dried reaction vessels under an argon atmosphere (99.996%). Protected Fmoc-
amino acids and coupling reagents were purchased from Novabiochem 
(Schwalbach, Germany), Iris Biotech GmbH (Marktredwitz, Germany) and 
Medalchemy (Alicante, Spain). All other chemicals and organic solvents were 
purchased from commercial suppliers at the highest purity available and used 
without further purification. Flash chromatographic purification was performed 
using silica gel 60 (40-63 m) from Merck at 1-1.5 atm pressure. 
Analysis. Analytical high-performance liquid chromatography (HPLC) was 
performed using an Amersham Pharmacia Biotech Äkta Basic 10F equipment, 
with a P-900 pump system, a reversed-phase YMC-ODS-A C18 column (4.6  
250 mm, 5 m), and UV detection (UV-900, 220 and 254 nm). The system was 
run at a flow rate of 1.0 ml/min over 30 min using H2O (0.1% (v/v) trifluoroacetic 
acid, [TFA]) and MeCN (0.1% (v/v) TFA) as solvents. Semi-preparative HPLC 
was carried out on a Beckmann instrument (system gold, solvent delivery module 
126, UV detector 166) using an YMC ODS-A column (20  250 mm, 5 m), at a 
flow rate of 8 ml/min. Linear gradients using H2O (0.1% (v/v) TFA) and MeCN 
(0.1% (v/v) TFA) were run over varying periods of time. HPLC-mass 
spectrometry (MS) analyses were performed on a Hewlett Packard Series HP 
1100 with a Finnigan LCQ mass spectrometer using a YMC Hydrosphere C18 
column (2.1 125 mm, 3 m). The system uses H2O (0.1% (v/v) formic acid) and 
MeCN (0.1% (v/v) formic acid) as eluents. High resolution mass spectrometry 
(HR-MS) was recorded on a Thermo Finnigan LTQ-FT (ESI-ICR) spectrometer. 
1H-NMR and 13C NMR spectra were recorded at 295 K on a 500 MHz Bruker 
DMX, 360 MHz Bruker AV or a 250 MHz Bruker AV spectrometer (Bruker, 
Karlsruhe, Germany). Chemical shifts (δ) are given in parts per million (ppm). 
Following solvent peaks were used as internal standards: dimethyl sulfoxide 
(DMSO)-d5: 2.50 ppm (
1H-NMR) and 39.52 ppm (13C-NMR); CHCl3: 7.26 ppm 
(1H-NMR) and 77.16 ppm (13C-NMR).[5] 
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GP1 Boc deprotection in solution. For Boc deprotection the compound was 
stirred for 30 min in TFA/DCM (1:1; v/v). The solvent was removed under 
reduced pressure to obtain the deprotected compound. 
GP2 Coupling with HATU/HOAt in solution. A solution of the acid (1 eq.), the 
amine (1 eq.), HATU (1.3 eq.), HOAt (1.3 eq.) and DIEA (5 eq.) in DMF was 
stirred over night. After removing the DMF under reduced pressure, the residue 
was redissolved in EtOAc, washed consecutively with saturated NH4Cl, saturated 
NaHCO3 and brine and dried over Na2SO4. After evaporation of the solvent the 
crude product was purified by reverse phase HPLC to afford the final compound. 
GP3 Methyl deprotection. The compound was dissolved in MeOH/H2O (3:1; 
v/v) and LiOH (5 eq.) was added. The reaction was stirred for 4 h to 12 h at 
ambient temperature while the course of reaction was followed by analytical 
HPLC. 
GP4 Loading of tritylchloride (TCP) resin. Solid phase synthesis was carried 
out using TCP resin (0.94 mmol/g) following standard Fmoc strategy. Fmoc-Aax-
OH (1.2 eq.) was attached to the TCP resin with N,N-diisopropylethylamine 
(DIEA, 2.5 eq.) in anhydrous DCM (10 ml/g resin) at room temperature for 1 h. 
The remaining trityl chloride groups were capped by addition of a solution of 
MeOH/DIEA (4/1, v/v, 1 ml/g resin) for 15 min. The resin was filtered and washed 
thoroughly with DCM (2x), N-methyl-2-pyrrolidone (NMP, 3x) and MeOH (5x). 
The loading capacity was determined by weight after drying the resin under 
vacuum. 
GP5 Solid phase N-Fmoc deprotection. The resin-bound Fmoc peptide was 
treated with 20% piperidine in NMP (v/v) for 5 min and a second time for 10 min. 
The resin was washed with NMP (5x). 
GP6 Solid phase coupling with HATU/HOAt. A solution of the acid (2 eq.), 
HATU (2 eq.), HOAt (2 eq.), DIEA (5 eq.) in NMP was added to the resin-bound 
free amine peptide and shaken for 1.5 h at room temperature. The resin was 
washed with NMP (5x). 
GP7 Solid phase N-Alloc deprotection. The resin was washed with DCM (3x) 
and then treated with a solution of tetrakis-triphenylphosphinepalladium (0.25 
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eq.) and phenylsilane (10 eq.) in DCM at ambient temperature. Care had to be 
taken due to gas evolution and the pressure had to be released from the reaction 
vessel from time to time. After 30 min of shaking, the mixture was filtered and the 
resin washed twice with a 0.5% solution of DDTC (sodium N,N-
diethyldithiocarbamate) in DMF and a 0.5% solution of DIEA in DMF. The 
washing procedure was repeated (3x) and the resin washed with NMP (5x). 
GP8 Guanidinylation. The amino-functionalized resin was added to a solution of 
10 eq. N,N’-bis-Boc-guanidinylpyrazole in absolute DCM (10 ml/g resin) in a 
closed reaction vessel. The mixture was shaken over night at room temperature. 
The resin was filtered and washed five times with DCM. The unconsumed 
guanidinylpyrazole could be recycled by concentration of the filtrate and 
recrystallization from hexane/ethyl acetate. 
GP9 Cleavage from TCP resin. The resin-bound compound was treated three 
times with a 20% solution of HFIP (hexafluoroisopropanol) in DCM (v/v) for 10 
min. The collected solutions were concentrated in vacuo. 
GP10 Boc, tBu and trityl deprotection in solution. Deprotection was achieved 
by treatment with TFA/TIS/H2O (95/2.5/2.5, v/v/v) in solution for 1 h. The mixture 
was coevaporated with toluene (3x). 
GP11 Reductive cleavage of benzyl and carboxybenzyl protecting groups. 
The starting material (1 eq.) was dissolved in MeOH. After addition of the catalyst 
(5% Pd/C, 15 mg/mmol starting material) the mixture was hydrogenated (1 atm, 
H2) at room temperature. The progress of the reaction was monitored by 
analytical HPLC until all starting material was consumed. The catalyst was 
removed by filtration over Celite® and the solvent removed under reduced 
pressure. 
GP12 Synthesis of ethers by Mitsunobu reaction. The aromatic alcohol (1 
eq.), the aminoalcohol (1.2 eq) and tributylphosphine (1.2 eq.) were dissolved in 
dry THF and stirred at 0 °C under argon atmosphere. Azodicarboxydipiperidide 
(ADDP, 1.2 eq.) was dissolved in absolute THF and added to the reaction 
mixture over a period of 4 h. The resulting suspension was allowed to warm to 
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room temperature over night. The solvent was removed and the residue purified 
by flash chromatography on silica gel. 
 
(S)-3-(2-(3-guanidinobenzamido)acetamido)-2-(4-isopropoxy-2,6-
dimethylbenzamido)propanoic acid) (1) 
O
OH
HN O
O
N
H
O
H
N
O
N
H
H2N
NH
C25H32N6O6
Exact Mass: 512,24
Mol. Wt.: 512,56
 
Preparation of compound 1 according to literature[6] gave 15.13 mg (26 µmol, 
22%) as colorless solid. 1H-NMR (500 MHz, DMSO): δ = 12.71 (bs, 1H), 9.95 
(bs, 1H), 8.79 (t, 3J = 5.8 Hz, 1H), 8.27 (d, 3J = 6.6 Hz, 1H), 8.02 (t, 3J = 5.7 Hz, 
1H), 7.77 (d, 3J = 7.9 Hz, 1H), 7.73 (s, 1H), 7.55-7.42 (m, 4H), 7.39 (d, 
3J = 9.1 Hz, 1H), 6.57 (s, 2H), 4.62-4.56 (m, 1H), 4.50-4.46 (m, 1H), 3.98-3.87 
(m, 3H), 3.91 (dd, 2J = 16.3 Hz, 3J = 5.9 Hz, 1H),  3.83 (dd, 2J = 16.3 Hz, 
3J = 5.8 Hz, 1H), 3.56-3.51 (m, 1H), 3.44-3.39 (m, 1H), 2.20 (s, 6H), 1.24 (d, 
3J = 6.0 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ = 171.9, 169.2, 165.7, 156.9, 
155.8, 135.7, 135.6, 135.4, 130.6, 129.7, 127.2, 125.2, 123.4, 114.0, 68.8, 52.0, 
42.5, 21.8, 19.1. RP-HPLC (10-90%, 30 min) Rt = 13.50 min. MS (ESI): m/z = 
513.2 [m+H]+, 535.2 [m+Na]+. HR-MS (ESI) calc. for C25H33N6O6
+: 513.24561; 
found: 513.24585. 
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(S)-3-(4-isopropoxybenzamido)-4-(4-(3-((4-methoxypyridin-2-
yl)amino)propoxy)phenyl)butanoic acid (2) 
N
O
N
H
O
COOH
HN O
O
C29H35N3O6
Exact Mass: 521,25
Mol. Wt.: 521,6
 
The deprotection of the ligand precursor 15 (336 mg, 0.71 mmol, 1.0 eq.) and 
coupling with 4-isopropoxybenzoic acid (166 mg, 0.92 mmol, 1.3 eq.) followed 
GP1 and GP2. The crude product was deprotected according GP3. 
Semipreparative HPLC purification yielded the title compound 2 (32.7 mg, 
62.7 µmol, 9%). 1H-NMR (500 MHz, DMSO): δ [ppm] = 12.87 (bs, 1H), 12.17 (bs, 
1H), 8.28 (bs, 1H), 8.13 (d, 3J = 8.3 Hz, 1H), 7.80 (d, 3J = 7.1 Hz, 1H), 7.72 (d, 3J 
= 8.8 Hz, 2H), 7.13 (d, 3J = 8.5 Hz, 2H), 6.94 (d, 3J = 8.8 Hz, 2H), 6.83 (d, 3J = 
8.6 Hz, 2H), 6.46 (dd, 3J = 7.0 Hz, 4J = 2.1 Hz, 1H), 6.33 (d, 4J = 1.9 Hz, 1H), 
4.72-4.65 (m, 1H), 4.44-4.37 (m, 1H), 4.01 (t, 3J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.46-
3.42 (m, 2H), 2.80 (dd, 2J = 13.6 Hz, 3J = 8.0 Hz, 1H), 2.73 (dd, 2J = 13.6 Hz, 3J = 
5.8 Hz, 1H), 2.52-2.48 (m, 1H), 2.41 (dd, 2J = 15.4 Hz, 3J = 6.2 Hz, 1H), 2.02-
1.97 (m, 2H), 1.27 (d, 3J = 6.0 Hz, 6H). 13C-NMR (125 MHz, DMSO): δ [ppm] = 
172.5, 165.1, 159.7, 156.8, 130.9, 130.1, 129.0, 126.5, 114.7, 114.1, 103.9, 99.4, 
69.3, 64.6, 56.4, 48.3, 40.1, 39.8, 38.7, 27.9, 21.7. RP-HPLC (10-90%): tR = 
17.63 min. MS (ESI): m/z (%) = 522.4 [m+H]+. HR-MS (ESI) calc. for 
C29H36N3O6
+: 522.25986; found: 522.25795. 
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(S)-3-(2-(3-guanidinobenzamido)acetamido)-2-(4-(3-(6-(3-mercaptopropan-
amido)hexanamido)propoxy)-2,6-dimethylbenzamido)propanoic acid (3) 
O
OH
HN O
O
N
H
H
N
O
O
H
N
O
N
H
H2N
NH
N
H
O
SH
C34H48N8O8S
Exact Mass: 728,33
Mol. Wt.: 728,86
 
Prepared from N-α-Fmoc-N-β-Alloc-l-diaminopropionic acid according the 
following reaction sequence: Loading of 1 g resin (real loading: ~693 µmol, GP4), 
Fmoc deprotection (GP5), coupling of 12 (GP6), Fmoc deprotection (GP5), 
coupling of 6-(tert-butoxycarbonyl)aminohexanoic acid (GP6), Fmoc deprotection 
(GP5), coupling of 3-(trityl)mercaptopropionic acid (GP6), Alloc deprotection 
(GP7), coupling of Fmoc-Gly-OH (GP6), Fmoc deprotection (GP5), coupling of 3-
Fmoc-aminobenzoic acid (GP6), Fmoc deprotection (GP5), guanidinylation 
(GP8), cleavage from the resin (GP9), Trityl and Boc deprotection (GP10). After 
semipreparative HPLC purification compound 3 (15.5 mg, 21.3 µmol, 3%) was 
obtained as colorless solid. 1H-NMR (500 MHz, DMSO): δ = 12.46 (bs, 1H), 9.95 
(s, 1H), 8.80 (t, 3J = 5.8 Hz, 1H), 8.31 (d, 3J = 7.0 Hz, 1H), 8.04 (t, 3J = 5.6 Hz, 
1H), 7.84 (t, 3J = 5.3 Hz, 2H), 7.76 (d, 3J = 7.8 Hz, 1H), 7.72 (s, 1H), 7.58-7.45 
(m, 4H), 7.39 (d, 3J = 8.9 Hz, 1H), 6.58 (s, 2H), 4.52-4.45 (m, 1H), 3.98-3.87 (m, 
3H), 3.82 (dd, 2J = 16.4 Hz, 3J = 5.7 Hz, 1H), 3.58-3.50 (m, 1H), 3.45-3.38 (m, 
1H), 3.18-3.15 (m, 2H), 3.03-3.00 (m, 2H), 2.66-2.61 (m, 2H), 2.35 (t, 3J = 6.9 Hz, 
2H), 2.24 (t, 3J = 8.0 Hz, 1H), 2.21 (s, 6H), 2.04 (t, 3J = 7.4 Hz, 2H), 1.83-1.78 (m, 
2H), 1.51-1.45 (m, 2H), 1.40-1.34 (m, 2H), 1.25-1.19 (m, 2H). 13C NMR (126 
MHz, DMSO-d6) δ = 172.0, 171.9, 169.7, 169.2, 169.1, 165.7, 158.0, 155.8, 
135.7, 135.6, 135.4, 130.7, 129.7, 127.2, 125.1, 123.4, 112.9, 65.1, 52.1, 42.5, 
38.4, 35.4, 35.3, 35.0, 34.0, 28.9, 28.9, 26.1, 25.0, 19.1. RP-HPLC (10-90%, 30 
min) Rt = 11.48 min. MS (ESI): m/z = 729.3 [m+H]
+, 751.3 [m+Na]+. HR-MS (ESI) 
calc. for C34H49N8O8S
+: 729.33941; found: 729.33903. 
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(S)-3-(4-(3-(6-(3-mercaptopropanamido)hexanamido)propoxy)benzamido)-4-
(4-(3-((4-methoxypyridin-2-yl)amino)propoxy)phenyl)butanoic acid (4) 
N
O
N
H
O
COOH
HN O
O
H
N
O
N
H
O
SH
C38H51N5O8S
Exact Mass: 737,35
Mol. Wt.: 737,91
 
After Boc deprotection of ligand precursor 15 (32 mg, 67.6 µmol, 1.0 eq.) 
according to GP1 the solvent was evaporated in vacuo. The deprotected 
compound was coupled with 17 (52 mg, 81.1 µmol, 1.2 eq.) (GP2) and 
deprotected according to GP3 and GP1. Semipreparative HPLC purification 
afforded the title compound 4 (4.05 mg, 5.49 µmol, 8%) as colorless solid. 1H-
NMR (500 MHz, DMSO): δ = 12.69 (bs, 1H), 12.17 (bs, 1H), 8.40 (bs, 1H), 8.15 
(d, 3J = 8.4 Hz, 1H), 7.87-7.82 (m, 2H), 7.79 (t, 3J = 6.4 Hz, 1H), 7.74 (d, 3J = 8.8 
Hz, 2H), 7.13 (d, 3J = 8.6 Hz, 2H), 6.96 (d, 3J = 8.8 Hz, 2H), 6.83 (d, 3J = 8.6 Hz, 
2H), 6.51 (dd, 3J = 7.2 Hz, 4J = 2.4 Hz, 1H), 6.36 (d, 4J = 2.3 Hz, 1H), 4.44-4.37 
(m, 1H), 4.04-3.99 (m, 4H), 3.88 (s, 3H), 3.46-3.42 (m, 2H), 3.20-3.16 (m, 2H), 
3.04-3.00 (m, 2H), 2.80 (dd, 2J = 13.6 Hz, 3J = 8.0 Hz, 1H), 2.73 (dd, 2J = 13.6 
Hz, 3J = 5.9 Hz, 1H), 2.66-2.61 (m, 2H), 2.53-2.48 (m, 1H), 2.41 (dd, 2J = 15.4 
Hz, 3J = 6.2 Hz, 1H), 2.35 (t, 3J = 6.9 Hz, 2H), 2.24 (t, 3J = 8.0 Hz, 1H), 2.07-1.98 
(m, 4H), 1.87-1.81 (m, 2H), 1.51-1.45 (m, 2H), 1.40-1.34 (m, 2H), 1.25-1.19 (m, 
2H). 13C-NMR (125 MHz, DMSO): δ = 172.6, 172.1, 170.0, 169.3, 165.1, 160.8, 
157.8, 156.8, 154.6, 131.0, 130.1, 129.0, 126.8, 114.2, 113.8, 104.4, 91.7, 65.5, 
64.5, 56.6, 48.4, 38.8, 38.4, 35.4, 28.9, 27.8, 26.1, 25.0, 20.0. HPLC (10-90%, 30 
min) tR = 15.43 min. MS (ESI): 738.5 [m+H]
+, 369.9 [m/2+H]+. HR-MS (ESI): calc. 
for C38H52N5O8S
+: 738.35311; found: 738.35471. 
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3-(Benzyloxycarbonylamino)-propan-1-ol (5) 
HO N
H
O
O
C11H15NO3
Exact Mass: 209,11
Mol. Wt.: 209,24
 
3-Aminopropanol (3.0 ml, 39.2 mmol, 1 eq.) and NaHCO3 (8.23 g, 98.0 mmol, 
2.5 eq.) were dissolved in 80 ml THF/H2O (1:1; v/v). After addition of 
benzylchloroformiate (5.60 ml, 39.2 mmol, 1 eq.) over a period of 30 min and 
stirring for 12 h the THF was removed. The aqueous phase was extracted with 
EtOAc, the organic phase washed with brine, dried over Na2SO4 and the solvent 
removed under reduced pressure. Purification via flash chromatography 
(hexane/EtOAc 2:3) gave 5 (6.31 g, 30.2 mmol, 77%) as colorless solid. 1H-NMR 
(250 MHz, DMSO): δ = 7.29-7.39 (m, 5H, Ar-H), 7.12 (t, 3J = 6.5 Hz, 1H, -NH-), 
5.00 (s,2H, -CH2-Ar), 4.40 (bs, 1H, -OH),  3.37-3.43 (m, 2H, -CH2-OH), 3.04 (q, 
2H, 3J = 6.5 Hz, -CH2-NH-),1.50-1.61 (m, 2H, -CH2-CH2-CH2-). 
13C-NMR 
(90 MHz, DMSO): δ = 156.3, 137.4, 128.5, 127.9, 127.8, 65.2, 58.5, 37.7, 32.7. 
RP-HPLC (50-100%, 30 min) Rt = 13.42 min. MS (ESI): m/z = 210.1 [m+H]
+, 
232.3 [m+Na]+. 
 
Allyl 3-hydroxypropylcarbamate (6) 
HO N
H
O
O
C7H13NO3
Exact Mass: 159,09
Mol. Wt.: 159,18  
3-Aminopropanol (3.00 g, 39.9 mmol, 1.0 eq.) and Na2CO3 (4.44 g, 41.9 mmol, 
1.05 eq.) were dissolved in 60 ml H2O/acetonitrile (2:1) and cooled to 0 °C. Allyl 
chloroformate (5.29 g, 43.9 mmol, 1.1 eq.) was added over 30 min and the 
mixture was allowed to warm to room temperature over night. After evaporation 
of acetonitrile, conc. HCl was added to the residue (pH 2) and taken up in EtOAc. 
The organic layer was dried over Na2SO4, filtered and the solvent was 
evaporated to give 5.77 g (36.2 mmol, 91%) of a colorless solid. 1H-NMR (360 
MHz, CDCl3): δ = 5.94 - 5.83 (m, 1H), 5.27 (dd, 
3J = 17.2 Hz, 2J = 1.4 Hz, 1H), 
5.18 (dd, 3J = 10.4 Hz, 2J = 1.2 Hz, 1H), 5.09 (bs, 1H), 4.53 (d, 3J = 5.4 Hz, 2H), 
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3.65 (t, 3J = 5.7 Hz, 2H), 3.32-3.30 (m, 2H), 2.44 (bs, 1H), 1.81-1.65 (m, 2H). 13C-
NMR (90 MHz, CDCl3): δ = 157.4, 133.0, 117.9, 65.9, 59.8, 37.9, 32.7. MS (ESI): 
160.0 [m+H]+. 
 
1-((4-bromo-3,5-dimethylphenoxy)methyl)benzene (7) 
Br
O
C15H15BrO
Exact Mass: 290,03
Mol. Wt.: 291,18
 
4-Bromo-3,5-dimethylphenole (5.00 g, 24.9 mmol, 1 eq.) was dissolved in 75 ml 
dry DMF and cooled to 0 °C. NaH (1.30 g, 29.9 mmol, 1.3 eq., 60% in paraffin oil) 
was added and the solution allowed to stir for 30 min. After addition of 
benzylbromide (2.95 ml, 24.9 mmol, 1 eq.) the solution was stirred for another 
2 h at room temperature. After addition of 50 ml saturated aqueous NH4Cl, the 
solution was extracted with diethylether and the organic layer washed with brine 
and dried over Na2SO4. The solvent was removed under reduced pressure and 
the crude product purified via flash chromatography (hexane/EtOAc 9:1) to give 7 
(6.47 g, 22.2 mmol, 89%) as colorless crystals. 1H-NMR (250 MHz, DMSO): δ = 
7.45-7.28 (m, 5H), 6.87 (s, 2H), 5.06 (s, 2H), 2.31 (s, 6H). 13C-NMR (125 MHz, 
CDCl3): δ = 157.3, 139.1, 136.9, 128.6, 128.0, 127.4, 118.6, 114.7, 70.1, 24.1. 
RP-HPLC (50-100%, 30 min) Rt = 22.66 min. 
 
tert-Butyl 4-(benzyloxy)-2,6-dimethylbenzoate (8) 
O
O O
C20H24O3
Exact Mass: 312,17
Mol. Wt.: 312,4
 
7 (5.50 g, 18.9 mmol, 1 eq.) was dissolved in 100 ml dry THF and cooled to 
-78 °C. Then, n-Butyllithium (2.5 m in hexane, 9.00 ml, 22.5 mmol, 1.2 eq.) was 
added and the solution allowed to stir for 30 min. After addition of Boc2O (4.15 g, 
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19 mmol, 1 eq.) the solution was again stirred for 30 min before it was allowed to 
come to room temperature within 1.5 h. The mixture was acidified with 1 n HCl, 
the THF evaporated and the aqueous phase extracted with EtOAc. The organic 
layer was washed with brine, dried over Na2SO4 and the solvent removed under 
reduced pressure. The crude product was purified via flash chromatography 
(hexane/EtOAc 26:1) to give 8 (5.58 g, 17.9 mmol, 95%) as a colorless solid. 
1H-NMR (250 MHz, DMSO): δ = 7.45-7.30 (m, 5H), 6.63 (s, 2H), 5.04 (s, 2H), 
2.22 (s, 6H), 1.40 (s, 9H). 13C-NMR (90 MHz, DMSO): δ = 168.4, 158.5, 138.7, 
137.4, 128.4, 127.8, 127.6, 122.4, 112.5, 80.7, 69.0, 27.6, 21.1. RP-HPLC (50-
100%, 30 min) Rt = 20.51 min. 
 
tert-Butyl 4-hydroxy-2,6-dimethylbenzoate (9) 
OH
O O
C13H18O3
Exact Mass: 222,13
Mol. Wt.: 222,28
 
Prepared from 8 (5.58 g, 17.9 mmol) according to GP11 gives 9 (3.96 mg, 
17.8 mmol, 100%) as a pale yellow liquid. 1H-NMR (250 MHz, DMSO): δ = 9.52 
(s, 1H), 6.43 (s, 2H), 2.17 (s, 6H), 1.51 (s, 9H). 13C-NMR (125 MHz, CDCl3): δ = 
169.2, 155.7, 137.1, 128.1, 114.4, 81.5, 28.3, 19.8. RP-HPLC (50-100%, 30 min) 
Rt = 8.80 min. 
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Benzyl 4-(4-(tert-butoxycarbonyl)-3,5-dimethylphenoxy)butylcarbamate (10) 
O
O O
C24H31NO5
Exact Mass: 413,22
Mol. Wt.: 413,51
H
N O
O  
Prepared from 9 (1.77 g, 7.96 mmol, 1 eq.) and 5 (1.83 g, 8.76 mmol, 1.1 eq.) 
according to GP12. Purification via flash chromatography (hexane/EtOAc 3:1) of 
the crude product gives 10 (3.16 g, 7.64 mmol, 96%) as a colorless oil. 1H-NMR 
(250 MHz, DMSO): δ = 7.38-7.29 (m, 5H), 6.61 (s, 2H), 5.01 (s, 2H), 3.97 (t, 3J = 
6.4 Hz, 2H), 3.15 (q, 3J = 6.4 Hz, 2H), 2.22 (s, 6H), 1.89-1.79 (m, 2H), 1.52 (s, 
9H). 13C-NMR (90 MHz, DMSO): δ = 168.4, 158.5, 156.2, 137.3, 135.9, 128.4, 
127.8, 127.8, 127.7, 113.4, 65.2, 65.1, 37.4, 29.1, 27.8, 19.5. RP-HPLC (50-
100%, 30 min) Rt = 17.54 min. MS (ESI): m/z = 436.3 [m+Na]
+. 
 
tert-Butyl 4-(4-(9H-fluoren-9-yl)methyl)-carbaminobutoxy)-2,6-dimethylben-
zoate (11) 
O
O O
H
N O
O
C31H35NO5
Exact Mass: 501,25
Mol. Wt.: 501,61
 
After deprotection of 10 (2.97 g, 7.19 mmol) according to GP11 the obtained oil 
was dissolved in 120 ml THF/H2O (1:1) and NaHCO3 (1.21 g, 14.4 mmol, 2 eq.) 
was added. After addition of N-(9-Fluorenylmethoxycarbonyloxy) succinimide 
(2.76 g, 8.19 mmol, 1.1 eq.) over a period of 30 min and stirring for 12 h the THF 
was removed. The aqueous phase was extracted with EtOAc, the organic phase 
washed with brine, dried over Na2SO4 and the solvent removed under reduced 
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pressure. Purification via flash chromatography (hexane/EtOAc 3:1) yields 11 
(3.41 g, 6.80 mmol, 95%) as a colorless solid. 1H-NMR (250 MHz, DMSO): δ = 
7.88 (d, 3J = 7.2 Hz, 1H), 7.68 (d, 3J = 7.2 Hz, 1H), 7.45-7.27 (m, 5H), 6.61 (s, 
2H), 4.31 (d, 3J = 6.8 Hz, 2H), 4.21 (t, 3J = 6.8 Hz, 1H), 3.96 (t, 3J = 6.4 Hz, 2H), 
3.14 (q, 3J = 6.4 Hz, 2H), 2.22 (s, 6H), 1.88-1.77 (m, 2H), 1.52 (s, 9H). 13C-NMR 
(90 MHz, DMSO): δ = 168.4, 161.2, 157.5, 143.9, 135.9, 136.0, 135.4, 133.3, 
129.5, 124.0, 121.2, 114.2, 113.4, 81.0, 80.7, 65.1, 53.9, 28.8, 27.9, 19.5. RP-
HPLC (50-100%, 30 min) Rt = 22.46 min. MS (ESI): m/z = 524.4 [m+Na]
+, 468.6 
[m-tBu+Na]+. 
 
4-(4-(9H-fluoren-9-yl)methyl)-carbaminobutoxy)-2,6-dimethylbenzoic acid 
(12) 
O
O OH
H
N O
O
C27H27NO5
Exact Mass: 445,19
Mol. Wt.: 445,51
 
Prepared from 11 (3.41 g, 6.80 mmol, 1 eq.) according to GP10. Purification via 
flash chromatography (hexane/EtOAc 1:2) yields 2.18 g (4.89 mmol, 72%) 12 as 
colorless solid. 1H-NMR (250 MHz, DMSO): δ = 12.68 (s, 1H), 7.88 (d, 3J = 
7.2 Hz, 1H), 7.68 (d, 3J = 7.2 Hz, 1H), 7.45-7.27 (m, 5H), 6.62 (s, 2H), 4.31 (d, 3J 
= 6.8 Hz, 2H), 4.21 (t, 3J = 6.8 Hz, 1H), 3.96 (t, 3J = 6.1 Hz, 2H), 3.13 (q, 3J = 
6.1 Hz, 2H), 2.25 (s, 6H), 1.88-1.78 (m, 2H). 13C-NMR (90 MHz, DMSO): δ = 
170.6, 158.5, 156.2, 144.0, 140.8, 136.2, 127.7, 127.7, 127.1, 125.2, 120.2, 
113.43 65.3, 65.1, 46.9, 37.3, 29.1, 19.9. RP-HPLC (10-90%, 30 min) Rt = 25.32 
min. MS (ESI): m/z = 929.4 [2m+K]+. 
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(S)-Methyl-3-(tert-butoxycarbonylamino)-4-(4-(3-hydroxypropoxy)phenyl) 
butanoat (13) 
O
NHBoc
CO2Me
HO
C19H29NO6
Exact Mass: 367,2
Mol. Wt.: 367,44
  
A solution of N-Boc-β-tyrosine methyl ester[6] (520 mg, 1.68 mmol, 1.0 eq.) and 
potassium carbonate (581 mg, 4.20 mmol, 2.5 eq.) in absolute DMF (15 ml) were 
stirred for 30 min at 0 °C. 3-Brom-1-propanol (161 µL, 1.85 mmol, 1.1 eq.) was 
added and the mixture was stirred over night while warming to room temperature. 
The solvent was evaporated in vacuo, the residue was taken up with 1 N HCl and 
extracted with EtOAc. The combined organic layers were washed with brine and 
dried over Na2SO4 and concentrated to dryness. The crude product was purified 
by flash chromatography (DCM/EtOAc 3:1) to give 562 mg (1.53 mmol, 91%) of a 
colorless oil. 1H-NMR (500 MHz, DMSO): δ = 7.06 (d, 3J = 8.5 Hz, 2H), 6.82 (d, 
3J = 8.3 Hz, 2H), 6.79 (d, 3J = 8.6 Hz, 1H), 4.51 (bs, 1H), 3.98 (t, 3J = 6.4 Hz, 2H), 
3.93-3.85 (m, 1H), 3.54 (s, 3H), 3.33-3.29 (m, 2H), 2.63-2.59 (m, 2H), 2.38 (d, 3J 
= 6.9 Hz, 2H), 1.86-1.80 (m, 2H), 1.32 (s, 9H). 13C-NMR (125 MHz, DMSO): δ  = 
171.3, 157.1, 154.8, 130.2, 130.1, 114.1, 77.6, 64.4, 57.3, 51.3, 49.4, 38.8, 32.1, 
28.2. RP-HPLC (10-100%): tR = 18.34 min. MS (ESI): m/z (%) = 757.1 [2m+Na]
+, 
390.2 [m+Na]+, 268.3 [m-Boc+H]+. 
 
(S)-Methyl-3-(tert-butoxycarbonylamino)-4-(4-(3-oxopropoxy)phenyl) 
butanoat (14) 
O
NHBoc
CO2Me
O
C19H27NO6
Exact Mass: 365,18
Mol. Wt.: 365,42
 
Compound 13 (562 mg, 1.53 mmol, 1.0 eq.) was dissolved in DMSO (15 ml) and 
IBX[7] (890 mg, 3.18 mmol, 2.0 eq.) was added. The suspension was stirred for 
additional 6 h at ambient temperature. DCM was added and the mixture was 
extracted with saturated Na2CO3. The organic layers were combined, washed 
with brine and dried over Na2SO4. The solvent was evaporated in vacuo and 
compound 14 was obtained as brown oil (584 mg). The compound was used 
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directly in the next step without further purification. 1H-NMR (360 MHz, DMSO): δ 
= 9.72 (t, 3J = 1.7 Hz, 1H), 7.08 (d, 3J = 8.6 Hz, 2H), 6.84 (d, 3J = 8.5 Hz, 2H), 
6.80 (d, 3J = 8.9 Hz, 1H), 4.24 (t, 3J = 5.9 Hz, 2H), 3.94-3.82 (m, 1H), 3.54 (s, 
3H), 2.87-2.83 (m, 2H), 2.64-2.35 (m, 2H), 2.44-2.33 (m, 2H), 1.32 (s, 9H). 13C-
NMR (90 MHz, DMSO): δ = 201.8, 171.3, 156.7, 154.8, 130.7, 130.1, 114.2, 
77.6, 61.5, 51.3, 49.3, 42.7, 28.2. RP-HPLC (10-90%): tR = 21.91 min. MS (ESI): 
m/z (%) = 388.1 [m+Na]+, 332.3 [m-tBu+Na]+, 266.1 [m-Boc+H]+. 
 
(S)-Methyl-3-(tert-butoxycarbonylamino)-4-(4-(3-(4-methoxypyridin-2-
ylamino)-propoxy)phenyl)butanoat (15) 
O
NHBoc
CO2Me
N
H
N
O
C25H35N3O6
Exact Mass: 473,25
Mol. Wt.: 473,56
 
Compound 14 (584 mg crude product, 1.60 mmol, 1 eq.) was dissolved in 
absolute DCM (50 ml). 2-Amino-4-methoxypyridine (238 mg, 1.92 mmol, 1.2 eq.) 
and 868 mg magnesium sulfate monohydrate (0.96 g, 7.99 mmol, 5 eq.) were 
added. After stirring the suspension for 1 h at room temperature sodium 
triacetoxyborohydride (1.90 g, 8.95 mmol, 5.6 eq.) was added and stirring was 
continued over night. After addition of 50 ml saturated NaHCO3 solution and 
further 30 min of stirring the organic layer was extracted twice with DCM (50 ml) 
and dried over Na2SO4. After filtration the solvent was concentrated to dryness 
and the crude product was purified by flash chromatography (DCM/EtOAc 1:1) to 
give 220 mg of a colorless oil (0.46 mmol, 29% over two steps). 1H-NMR (500 
MHz, DMSO): δ [ppm] = 7.77 (d, 3J = 5.8 Hz, 1H), 7.07 (d, 3J = 8.5 Hz, 2H), 6.86-
6.84 (m, 3H), 6.49 (t, 3J = 5.5 Hz, 1H), 6.11 (dd, 3J = 5.8 Hz, 4J = 2.2 Hz, 1H), 
5.94 (d, 4J = 2.2 Hz, 1H), 3.99 (t, 3J = 6.3 Hz, 2H), 3.92-3.85 (m, 1H), 3.69 (s, 
3H), 3.54 (s, 3H), 3.36-3.32 (m, 2H), 2.65-2.56 (m, 2H), 2.37 (d, 3J = 6.9 Hz, 2H), 
1.96-1.90 (m, 2H), 1.32 (s, 9H). 13C-NMR (125 MHz, DMSO): δ [ppm] = 171.4, 
166.0, 160.7, 157.1, 154.9, 148.7, 130.4, 130.2, 114.2, 100.9, 90.7, 77.7, 65.3, 
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54.6, 51.4, 49.5, 37.8, 28.9, 28.3. RP-HPLC (10-90%): tR = 19.15 min. MS (ESI): 
m/z (%) = 474.2 [m+H]+, 418.3 [m-tBu+H]+, 374.3 [m-Boc+H]+. 
 
4-[3-(((Allyloxy)carbonyl)amino)propoxy]benzoic acid (16) 
O OH
O
H
N O
O
C14H17NO5
Exact Mass: 279,11
Mol. Wt.: 279,29
 
Compound 16 was prepared from methyl 4-hydroxy-benzoate (1.00 g, 
6.57 mmol, 1.0 eq.) and allyl-3-hydroxypropylcarbamate 6 (1.15 g, 7.23 mmol, 
1.2 eq.) according to GP12 (hexane/EtOAc 2:1). The compound was deprotected 
according to GP3 to give a colorless solid (1.77 g, 6.35 mmol, 97%). 1H-NMR 
(360 MHz, DMSO): δ = 12.59 (bs, 1H), 7.89-7.86 (d, 3J = 10.8 Hz, 2H), 7.29 (t, 3J 
= 5.3 Hz, 1H), 7.01-6.98 (d, 3J = 10.8 Hz, 2H), 5.90 (m, 1H), 5.21 (m, 2H), 4.46 
(d, 3J = 5.3 Hz, 2H), 4.06 (t, 3J = 6.2 Hz, 2H), 3.15 (m, 2H), 1.87 (m, 2H). 13C-
NMR (90 MHz, DMSO): δ = 166.9, 162.2, 155.9, 133.8, 131.3, 122.9, 116.9, 
114.2, 65.4, 64.2, 37.2, 29.0. RP-HPLC (10-90%, 30 min) tR = 16.97 min. MS 
(ESI): 876.0 [3m+K]+,860.1 [3m+Na]+, 597.2 [2m+K]+, 581.2 [2m+Na]+, 280.1 
[m+H]+. 
 
4-(3-(6-(3-(Tritylthio)propanamido)hexanamido)propoxy)benzoic acid (17) 
O OH
O
H
N
O
N
H
O
S
C38H42N2O5S
Exact Mass: 638,28
Mol. Wt.: 638,82
 
Prepared from 16 (77 mg, 0.28 mmol) according to the following reaction 
sequence: Loading of 0.25 g resin (real loading: ~186 µmol, GP4), Alloc 
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deprotection (GP7), coupling of Fmoc-6-aminohexanoic acid (GP6), Fmoc 
deprotection (GP5), coupling of 3-(Trityl)mercaptopropionic acid (GP6), cleavage 
from the resin (GP9). The title compound 16 (95 mg, 149 µmol, 80%) was 
obtained as colorless solid. 1H-NMR (500 MHz, DMSO): δ = 12.66 (bs, 1H), 7.90-
7.87 (m, 3H), 7.81 (t, 3J = 5.5 Hz, 1H), 7.34-7.22 (m, 15H), 6.99 (d, 3J = 8.6 Hz, 
2H), 4.03 (t, 3J = 6.2 Hz, 2H), 3.20-3.16 (m, 2H), 2.98-3.94 (m, 2H), 2.21 (t, 3J = 
7.3 Hz, 2H), 2.12 (t, 3J = 7.2 Hz, 2H), 2.02 (t, 3J = 7.5 Hz, 2H), 1.86-1.81 (m, 2H), 
1.48-1.42 (m, 2H), 1.36-1.30 (m, 2H), 1.21-1.15 (m, 2H). 13C-NMR (125 MHz, 
DMSO): δ = 172.1, 169.8, 167.1, 162.2, 144.5, 131.4, 129.1, 128.1, 126.8, 123.1, 
114.2, 66.0, 65.5, 38.4, 35.4, 35.3, 34.0, 28.9, 28.8, 27.6, 26.1, 25.1. RP-HPLC 
(10-90%, 30 min) tR = 26.17 min. MS (ESI): 1315.5 [2m+K]
+,1299.4 [2m+Na]+, 
1277.3 [2m+H]+, 661.3 [m+Na]+, 638.9 [m+H]+. 
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